43% Of Medicaid MCO Plans In 2021 Covered All Approved Medications To Treat Alcohol Use Disorder

Of the 241 comprehensive Medicaid managed care organization (MCO) plans operating in 2021, 42.7% (103 plans) covered all four medications—acamprosate, oral naltrexone, injectable naltrexone, and disulfiram—approved to treat alcohol use disorder (AUD). The medications were generally available without prior authorization or quantity limits, except for injectable naltrexone.

About 90% of the MCO plans covered at least one medication for AUD. Within this group,

Acamprosate was covered by 54.7% of the plans (132 plans). Of these plans, 75.8% did not require prior authorization or quantity limits.

Oral naltrexone was covered by 84.2% of the plans . . .